中华泌尿外科杂志
中華泌尿外科雜誌
중화비뇨외과잡지
CHINESE JOURNAL OF UROLOGY
2011年
10期
679-681
,共3页
陈海昕%张冠%方自林%王翔%刘乃波
陳海昕%張冠%方自林%王翔%劉迺波
진해흔%장관%방자림%왕상%류내파
膀胱肿瘤%良性前列腺增生%经尿道手术
膀胱腫瘤%良性前列腺增生%經尿道手術
방광종류%량성전렬선증생%경뇨도수술
Bladder neoplasms%Benign prostatic hyperplasia%Transurethral resection
目的 探讨合并BPH的非肌层浸润性膀胱癌患者同期行经尿道电切(TUR)手术的疗效和安全性.方法 合并BPH的非肌层浸润性膀胱癌患者46例(A组)同期行TURBt和TURP治疗,非肌层浸润性膀胱癌仅行TURBt的男性患者69例(B组)作为对照组.A组年龄54~80岁,平均69岁;肿瘤单发37例、多发9例,肿瘤直径0.5 ~3.5 cm,平均2.8 cm.B组55~82岁,平均70岁;肿瘤单发54例、多发15例;肿瘤直径0.5~24.0 cm,平均2.9 cm;2组比较差异无统计学意义(P>0.05).结果 2组均顺利完成手术.随访24 - 96个月,平均44个月.2组复发率分别为50.0%( 23/46)、50.7% (35/69),首次无复发间期分别为20、18个月,肿瘤进展率分别为6.5%、7.2%,2组差异均无统计学意义(P>0.05).A组术后发生前列腺窝内膀胱癌复发2例、B组l例,均为T1G3肿瘤.结论 同期行TUR手术治疗浅表性、低级别膀胱肿瘤合并BPH患者安全可行,但对于T1G3患者应慎重.
目的 探討閤併BPH的非肌層浸潤性膀胱癌患者同期行經尿道電切(TUR)手術的療效和安全性.方法 閤併BPH的非肌層浸潤性膀胱癌患者46例(A組)同期行TURBt和TURP治療,非肌層浸潤性膀胱癌僅行TURBt的男性患者69例(B組)作為對照組.A組年齡54~80歲,平均69歲;腫瘤單髮37例、多髮9例,腫瘤直徑0.5 ~3.5 cm,平均2.8 cm.B組55~82歲,平均70歲;腫瘤單髮54例、多髮15例;腫瘤直徑0.5~24.0 cm,平均2.9 cm;2組比較差異無統計學意義(P>0.05).結果 2組均順利完成手術.隨訪24 - 96箇月,平均44箇月.2組複髮率分彆為50.0%( 23/46)、50.7% (35/69),首次無複髮間期分彆為20、18箇月,腫瘤進展率分彆為6.5%、7.2%,2組差異均無統計學意義(P>0.05).A組術後髮生前列腺窩內膀胱癌複髮2例、B組l例,均為T1G3腫瘤.結論 同期行TUR手術治療淺錶性、低級彆膀胱腫瘤閤併BPH患者安全可行,但對于T1G3患者應慎重.
목적 탐토합병BPH적비기층침윤성방광암환자동기행경뇨도전절(TUR)수술적료효화안전성.방법 합병BPH적비기층침윤성방광암환자46례(A조)동기행TURBt화TURP치료,비기층침윤성방광암부행TURBt적남성환자69례(B조)작위대조조.A조년령54~80세,평균69세;종류단발37례、다발9례,종류직경0.5 ~3.5 cm,평균2.8 cm.B조55~82세,평균70세;종류단발54례、다발15례;종류직경0.5~24.0 cm,평균2.9 cm;2조비교차이무통계학의의(P>0.05).결과 2조균순리완성수술.수방24 - 96개월,평균44개월.2조복발솔분별위50.0%( 23/46)、50.7% (35/69),수차무복발간기분별위20、18개월,종류진전솔분별위6.5%、7.2%,2조차이균무통계학의의(P>0.05).A조술후발생전렬선와내방광암복발2례、B조l례,균위T1G3종류.결론 동기행TUR수술치료천표성、저급별방광종류합병BPH환자안전가행,단대우T1G3환자응신중.
Objective To evaluate the clinical significance of simultaneous transurethral resection (TUR) of a bladder tumor and the prostate in the treatment of non-muscle invasive bladder cancer with benign prostatic hyperplasia (BPH).Methods Patients were divided into two groups.Group A contained 46 male patients who accepted TUR for the treatment of both bladder cancer and benign prostatic hyperplasia.Group B contained 69 male patients who accepted TURBt only.Clinical data were retrospectively collected and analyzed to compare clinical outcomes and safety in these two groups.Results The bladder cancer recurrence rates in group A and B were 50.0% and 50.7%,the average recurrence free time was 20 and 18 months,and the progression rates were 6.5% and 7.2%,respectively.There were no significant differences between the two groups for either average recurrence free time or progression rates (P > 0.05).Recurrences in the prostatic urethra were found in two cases in group A and one case in group B and all three cases were in T1 G3.Conclusions Simultaneous TUR for bladder tumor and the prostate can be safely and effectively performed in terms of oncologica] control in patients who have non-muscle invasive and low grade bladder tumors ( T1G1 - G2 ) with lower urinary tract obstruction caused by BPH.But this procedure should be cautiously performed on patients with T1 G3 bladder tumors.